systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-26Research ArticleКАРДИОЛОГИЯCARDIOLOGYЧто лежит в основе эффективности лечения периндоприлом больных ишемической болезнью сердца – небольшое снижение артериального давления или нечто большее? Итоги и перспективы исследования EUROPAХирмановВ. Н.noemail@neicon.ruСанкт-Петербургская государственная медицинская академия им. И.И.МечниковаRussian Federation20042312202213437Copyright © Хирманов В.Н., 20222022Хирманов В.Н.Хирманов В.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/26

Завершено рандомизированное двойное слепое плацебо-контролируемое, многоцентровое исследование EUROPA (European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease). Его результаты опубликованы в журнале Lancet (N 9386 за 2003 г.) [1] и впервые обсуждены на съезде Европейского общества кардиологов в сентябре прошедшего года. Это новое крупное международное исследование имеет большое значение для развития многих аспектов клинической и теоретической кардиологии. Один из них – причина достоверных преимуществ нового подхода к лечению больных ишемической болезнью сердца – представляется актуальным для обсуждения. Но прежде необходимо кратко сформулировать основные положения исследования EUROPA. Цель исследования. Как это следует из названия проекта, цель состояла в решении вопроса о том, эффективно ли применение ингибитора ангиотензинпревращающего фермента (ИАПФ) периндоприла (хорошо известного отечественным врачам под названием "Престариум") для лечения больных со стабильным течением ишемической болезни сердца (ИБС), не осложненной сердечной недостаточностью.

ReferencesFox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators/Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators/Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 1451–3.Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 1451–3.Chobanian A.V, Bakris G.L, Black H.R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (19): 2560–72.Chobanian A.V, Bakris G.L, Black H.R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (19): 2560–72.European Society of Hypertension-European Society of Cardiology Guidelines Committee/2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011–53.European Society of Hypertension-European Society of Cardiology Guidelines Committee/2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011–53.Benetos A, Thomas F, Bean K.E, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21 (9): 1635–40.Benetos A, Thomas F, Bean K.E, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21 (9): 1635–40.Boutitie F, Gueyffier F, Pocock S et al. INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta - analysis of individual - patient data. Ann Intern Med 2002; 136 (6): 438–48.Boutitie F, Gueyffier F, Pocock S et al. INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta - analysis of individual - patient data. Ann Intern Med 2002; 136 (6): 438–48.Candido R, Jandeleit-Dahm K.A, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin - converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106 (2): 246–53.Candido R, Jandeleit-Dahm K.A, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin - converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106 (2): 246–53.Cook N.R, Cohen J, Hebert P.R et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155 (7): 701–9.Cook N.R, Cohen J, Hebert P.R et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155 (7): 701–9.Mac Mahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 (8692): 765–74.Mac Mahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 (8692): 765–74.Britten M.B, Zeiher A.M, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245 (4): 315–27.Britten M.B, Zeiher A.M, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245 (4): 315–27.Brown N.J, Agirbasli M.A, Williams G.H et al. Effect of activation and inhibition of the renin - angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6): 1225–32.Brown N.J, Agirbasli M.A, Williams G.H et al. Effect of activation and inhibition of the renin - angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6): 1225–32.Dzau V.J, Bernstein K, Celermajer D et al.Dzau V.J, Bernstein K, Celermajer D et al.Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin - converting enzyme inhibitors in humans. Circulation 1997; 95 (5): 1115–8.Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin - converting enzyme inhibitors in humans. Circulation 1997; 95 (5): 1115–8.Lazar H, Lonn E, Luscher T et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16 (2): 149–60.Lazar H, Lonn E, Luscher T et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16 (2): 149–60.Marui N, Offermann M.K, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant - sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92 (4): 1866–74.Marui N, Offermann M.K, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant - sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92 (4): 1866–74.Matsumoto K, Morishita R, Moriguchi A et al. Inhibition of neointima by angiotensin - converting enzyme inhibitor in porcine coronary artery balloon - injury model. Hypertension 2001; 37 (2): 270–4.Matsumoto K, Morishita R, Moriguchi A et al. Inhibition of neointima by angiotensin - converting enzyme inhibitor in porcine coronary artery balloon - injury model. Hypertension 2001; 37 (2): 270–4.Vaughan D.E, Lazos S.A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin - angiotensin system and thrombosis. J Clin Invest 1995; 95 (3): 995–1001.Vaughan D.E, Lazos S.A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin - angiotensin system and thrombosis. J Clin Invest 1995; 95 (3): 995–1001.Bartels G.L, Van den Heuvel A.F.M, Van Veldhuisen D.J, Van der Ent M, Remme W.J. Acute anti - ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol 1999; 83 (3): 332–6.Bartels G.L, Van den Heuvel A.F.M, Van Veldhuisen D.J, Van der Ent M, Remme W.J. Acute anti - ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol 1999; 83 (3): 332–6.Gomma A.H, Fox K.M, on behalf of the EUROPA Investigators / The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15 (2): 169–79.Gomma A.H, Fox K.M, on behalf of the EUROPA Investigators / The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15 (2): 169–79.Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators/PERTINENT – perindopril - thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub - study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17 (1): 83–91.Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators/PERTINENT – perindopril - thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub - study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17 (1): 83–91.

The authors declare that there are no conflicts of interest present.